Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by MrMugsyon Jan 09, 2022 7:34pm

341 Views

Post# 34298541

2022 Trends ...

Investment in biotech picks up

After record investment poured into biotech at the start of the pandemic, 2021 was a bumpy year for the sector. Stocks of major pharmaceutical companies languished even as the industry was cranking out billions of doses of life-saving vaccines in record time.

But according to Dan Legault, CEO of Toronto-based Antibe Therapeutics, investment in biotech should pick up again in the coming year.

“The pullback was too fast and too strong,” he says. Legault puts the investment chill down to a lack of major mergers or acquisitions of late but says that with several promising developments on the horizon there is still “huge money” looking to invest in the sector.
-------------

Can't tell if Dan is talking about biotech in general, ATE or both. Hahaha !